Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMO | O15229 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PNLIP | P16233 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484623 | 0.73 | PRKCI (0.41) | KDM4EMAPTKMT2ATSHRPDE7A | |
| SCHEMBL5541190 | 0.72 | ALDH1A1 (0.41) | SMN1; SMN2TP53KDM4EKMT2ATSHR | |
| SCHEMBL1964539 | 0.70 | CYP3A4 (0.56) | MAPTKMT2ATSHRPNLIPPDE7A | |
| SCHEMBL15652951 | 0.70 | ALDH1A1 (0.34) | TP53KDM4EKMOKMT2ATSHR | |
| SCHEMBL632218 | 0.69 | CYP3A4 (0.46) | SMN1; SMN2TSHRPDE7ARHEBCYP3A4 | |
| SCHEMBL3484014 | 0.69 | KCNA3 (0.40) | SMN1; SMN2KDM4EMAPTKMT2ATSHR | |
| SCHEMBL3484991 | 0.68 | PARP1 (0.44) | — | |
| SCHEMBL3485030 | 0.68 | MAPT (0.35) | KDM4EMAPTKMT2ARAB9APDE7A | |
| SCHEMBL3484137 | 0.68 | MRGPRX4 (0.42) | SMN1; SMN2KDM4EMAPTRAB9APDE7A | |
| SCHEMBL3484574 | 0.68 | CYP3A4 (0.35) | KDM4EMAPTKMT2ATSHRPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | SMN1; SMN2 4526/4885TP53 1105/4885KDM4E 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.